Annual report pursuant to Section 13 and 15(d)

DESCRIPTION OF BUSINESS (Details Narrative)

v3.21.1
DESCRIPTION OF BUSINESS (Details Narrative)
12 Months Ended
Jul. 17, 2019
Jul. 15, 2019
shares
Dec. 31, 2020
US [Member]      
Description Of Business [Line Items]      
Orphan drug designation provides market exclusivity period after marketing approval     7 years
EU [Member]      
Description Of Business [Line Items]      
Orphan drug designation provides market exclusivity period after marketing approval     10 years
Orphan drug designation provides additional marketing exclusivity period     2 years
Telemynd [Member]      
Description Of Business [Line Items]      
Common stock shares, stock split ratio   1  
Emmaus Life Sciences, Inc. [Member]      
Description Of Business [Line Items]      
Reverse split, conversion ratio 0.167    
Reverse split 1-for-6